Literature DB >> 1574566

Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining.

M Maes1, J Lambrechts, E Bosmans, J Jacobs, E Suy, C Vandervorst, C de Jonckheere, B Minner, J Raus.   

Abstract

Several studies have reported a suppressed immune function (e.g. blast transformation) during depression. In an attempt to define the cellular basis of the reported immune disorders, the present study investigates the leukocyte cell subset profile of minor, simple major, and melancholic depressives, versus normal controls. We have counted the number of white blood cells (WBC) lymphocytes, monocytes, and granulocytes, while the number of lymphocyte (sub)populations has been identified by phenotype, using monoclonal antibody staining in conjunction with flow cytometry. The following cell surface antigens were determined: CD3+ (pan T), CD19+ (pan B), CD4+ (T helper/inducer), CD8+ (T suppressor/cytotoxic), CD4+CD45RA (T-memory cells), CD4+CD45RA+ (T-virgin cells), surface Ig, class II MHC HLA-DR, and CD25+ (IL-2 receptor). By means of pattern recognition methods, we established distinct immunological changes in minor and simple major depressed and in melancholic patients, setting them apart from the reference population. Depression, per se, is characterized by a higher number of WBC, monocytes, class II MHC HLA-DR, and memory T cells. Minor and simple major depressives exhibited an increased T helper/suppressor ratio. Increased numbers of IL-2 receptor bearing cells are a hallmark for major depression. Melancholics showed an increased number of pan T, pan B and T suppressor/cytotoxic cells. It was concluded that the established immune cell profile of depressed patients may point towards the existence of a systemic immune activation during that illness.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1574566     DOI: 10.1017/s0033291700032712

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  59 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

Review 3.  Neuroinflammation and comorbidity of pain and depression.

Authors:  A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal:  Pharmacol Rev       Date:  2013-12-11       Impact factor: 25.468

4.  Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia.

Authors:  Toru Nakamura; Stephan K Schwander; Robert Donnelly; Felix Ortega; Fumiharu Togo; Gordon Broderick; Yoshiharu Yamamoto; Neil S Cherniack; David Rapoport; Benjamin H Natelson
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 6.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

7.  Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.

Authors:  M J Robertson; R S Schacterle; G A Mackin; S N Wilson; K L Bloomingdale; J Ritz; A L Komaroff
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

8.  Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder.

Authors:  Marcin Siwek; Magdalena Sowa-Kućma; Krzysztof Styczeń; Paulina Misztak; Rafał J Nowak; Bernadeta Szewczyk; Dominika Dudek; Janusz K Rybakowski; Gabriel Nowak; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

9.  Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders.

Authors:  Diana Ahmetspahic; Kathrin Schwarte; Oliver Ambrée; Christian Bürger; Vladislava Falcone; Katharina Seiler; Mehrdad Rahbar Kooybaran; Laura Grosse; Fernand Roos; Julia Scheffer; Silke Jörgens; Katja Koelkebeck; Udo Dannlowski; Volker Arolt; Stefanie Scheu; Judith Alferink
Journal:  J Neuroimmune Pharmacol       Date:  2017-09-13       Impact factor: 4.147

Review 10.  Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma?

Authors:  Andrea Danese; Stephanie J Lewis
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.